Date: March 30th, 2018

NanoMab Announces First NSCLC Patient Dosed in FIH of 99mTc-NM-01

Shanghai, China, March 30th, 2018. NanoMab today announced dosing of the first patients for its FIH of 99mTc-NM-01 in patients with non-small cell lung cancer at SGH.

99mTc-NM-01 is a camelid single domain antibody-based imaging agent for the non-invasive and whole body assessment of PD-L1 expression in patients before or during immuno-oncology treatment.